Desvenlafaxine Extended Release Tablets 25 mg, 50 mg and 100 mg

Lupin Limited

Revision date : 2022-05-24

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
GHS07
Health risk rating 4
Safety risk rating 1
Environmental risk rating 5

General Information

Revision date

2022-05-24

Product name

Desvenlafaxine Extended Release Tablets 25 mg, 50 mg and 100 mg

Manufacturer Name

Lupin Limited

Icons in SDS

GHS07

Company Information

company name

Lupin Limited

Section 2

SECTION 2: Hazards identification

WARNING Short Term Harmful if swallowed Individuals taking monoamine oxidase (MAO) inhibitors should avoid exposure to this material. Long Term Repeat-dose studies in animals have shown a potential to cause adverse effects on liver. Known Clinical Effects Ingestion of this material may cause effects similar to those seen in clinical use including dizziness, insomnia, nausea, constipation, vomiting, dry mouth, nervousness, anxiety, tremors, impotence, abnormal dreams, abnormal ejaculation, and sweating. Signs and symptoms associated with non-fatal over dosage were drowsiness, vomiting, rapid heart rate, nausea, dizziness, agitation, and tremor.

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.